Showing 4651-4660 of 8791 results for "".
- Nu Skin Kicks Off Its Global Day of Service with Projects for Childrenhttps://practicaldermatology.com/news/nu-skin-kicks-off-its-global-day-of-service-with-projects-for-children/2461233/Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts. To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to b
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a
- Message from ASLMS President Dr. Paul M. Friedmanhttps://practicaldermatology.com/news/message-from-aslms-president-dr-paul-m-friedman/2461221/Dr. Paul M. Friedman, president of the American Society for Laser Medicine and Surgery (ASLMS), is calling on members to expand philanthropic programs that can help change lives with lasers. “In the coming year, I will be looking to the membership to bring their talents forwa
- Cynosure Upgrades PicoSure System with PicoSure Pro Devicehttps://practicaldermatology.com/news/cynosure-upgrades-picosure-system-with-picosure-pro-device/2461220/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. An FDA-cleared 755nm picosecond laser, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide safe and effec
- University of Bradford Propels Skin Microbiome Researchhttps://practicaldermatology.com/news/university-of-bradford-propels-skin-microbiome-research/2461219/University of Bradford scientists are helping open new areas of research into the skin microbiome. Much like the gut microbiome, the skin has its own community of microorganisms, whose job is to protect us from infection and maintain a healthy state. However, scientists are only now beg
- FDA Accepts sBLA for Priority Review for Dupixent in PNhttps://practicaldermatology.com/news/fda-accepts-sbla-for-priority-review-for-dupixent-in-pn/2461218/FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) from Sanofi and Regeneron to treat adults with prurigo nodularis. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by dat
- Lullage Launches in US on International Skin Pigmentation Dayhttps://practicaldermatology.com/news/lullage-launches-in-us-on-international-skin-pigmentation-day/2461213/Lullage, known as Bella Aurora in Europe and Asia, celebrates International Skin Pigmentation Day to raise awareness about the prevalence of skin pigmentation conditions and the
- Crown to Acquire Aesthetic Product Portfolio from Eclipsehttps://practicaldermatology.com/news/crown-to-acquire-aesthetic-product-portfolio-from-eclipse/2461208/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions. "We
- June Risser Named General Manager of Premium Skincare Business Unit at Crown Laboratorieshttps://practicaldermatology.com/news/june-risser-named-general-manager-of-premium-skincare-business-unit-at-crown-laboratories/2461207/June Risser is Crown Laboratories, Inc.’s new General Manager of Premium Skincare. She will lead the global business unit which includes StriVectin and Vita Liberata, and she will hold a position on the Executive Leadership Team. Prior to Crown, she was General Man
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class.